A Randomized, Double Blind, Multi-center, Placebo-Controlled Exploratory Study of AS-3201 in Patients with Diabetic Sensorimotor Polyneuropathy

Authors [No authors listed]
Category Primary study
Registry of TrialsJapan Pharmaceutical Information Center
Year 2012
Links ICTRP
INTERVENTION: Intervention name : AS‐3201 (ranirestat) Dosage And administration of the intervention : AS‐3201 20 mg, Oral administration Control intervention name : Placebo Dosage And administration of the control intervention : Oral administration CONDITION: Diabetic peripheral neuropathy PRIMARY OUTCOME: Nerve conduction velocity SECONDARY OUTCOME: F‐wave minimum latency, clinical symptoms and signs INCLUSION CRITERIA: Patients with DPN who satisfy the following inclusion criteria ‐Patients who have DPN symptoms, signs and abnormal nerve conduction on the basis of pre‐defined criteria ‐Outpatients etc.
Epistemonikos ID: 9ed429067675423a2e1677436cc3ba9be06a8765
First added on: Aug 22, 2024